Pfizer Champions a New Era in Personalized Cancer Care at ASCO 2025 Annual Meeting
Pfizer Inc. (NYSE: PFE), a global leader in biopharmaceutical innovation, announced its robust presence at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, which will be held in Chicago from May 30 to June 3. The company plans to unveil data from over 60 abstracts, including company-sponsored, investigator-led, and collaborative research efforts. With nine oral presentations and six rapid oral presentations scheduled, Pfizer aims to spotlight the breadth and depth of its oncology portfolio, which spans a wide spectrum of malignancies including breast, genitourinary, hematologic, thoracic, and colorectal cancers.
This year’s ASCO meeting represents a critical juncture for Pfizer Oncology, reflecting not only the culmination of years of scientific research but also the company’s sharpened focus on delivering breakthrough medicines with meaningful clinical outcomes. According to Dr. Chris Boshoff, Chief Scientific Officer and President of Research & Development at Pfizer, 2025 has already marked several pivotal achievements for the company’s oncology division.
“This has already been a significant year for Pfizer’s Oncology pipeline, with multiple Phase 3 data readouts and regulatory approvals, and the initiation of pivotal registrational programs across our major tumor areas of focus,” said Boshoff. “The depth and diversity of our data presentations at ASCO are building on that momentum to bring us closer to our goal of delivering eight breakthrough cancer medicines by 2030.”
Major Late-Breaking Data Sets to Be Unveiled
Pfizer’s presence at ASCO will be anchored by two highly anticipated late-breaking oral presentations featured in the embargoed pre-meeting press briefing on May 27.
The first is the primary analysis of the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and the chemotherapy regimen mFOLFOX6. This study targets patients with BRAF V600E-mutant metastatic colorectal cancer—a particularly aggressive form of the disease with limited treatment options. The BREAKWATER trial’s primary endpoints include overall survival (OS) and progression-free survival (PFS), and its findings may potentially reshape the standard of care for this subset of patients.
The second late-breaking presentation will focus on the VERITAC-2 study, a Phase 3 trial evaluating the investigational agent vepdegestrant in partnership with Arvinas. This study explores vepdegestrant in estrogen receptor-positive, HER2-negative (ER+/HER2-) advanced or metastatic breast cancer, a population that continues to represent an unmet medical need despite advances in endocrine therapies. The primary data release will focus on PFS, offering the first insight into how this oral selective estrogen receptor degrader (SERD) performs in a Phase 3 setting.
Five-Year Survival and First-Time Combination Data in Prostate Cancer and Multiple Myeloma
Beyond the headline-grabbing late-breakers, Pfizer will also present updates from other cornerstone programs in its oncology franchise. Among these is the five-year survival data from the ARCHES study, a Phase 3 trial evaluating XTANDI® (enzalutamide) combined with androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC). The long-term follow-up provides critical data on the durability of treatment benefit and patient outcomes over extended periods—a key concern for both clinicians and patients.
In the hematologic malignancy space, Pfizer will unveil early combination data from the ongoing MagnetisMM-6 trial. This study evaluates ELREXFIO® (elranatamab), a bispecific antibody targeting BCMA, in combination with daratumumab and lenalidomide for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). This triple-agent approach may offer a powerful frontline option for patients who are often underserved due to age or comorbidities.
Pioneering ADC + Immunotherapy Combinations in Thoracic and Head & Neck Cancers
Pfizer is also advancing novel approaches that integrate cutting-edge antibody-drug conjugates (ADCs) with established immunotherapies to unlock new therapeutic synergies. At ASCO 2025, the company will present early data from Phase 1 trials investigating two next-generation vedotin-based ADCs in combination with the PD-1 inhibitor pembrolizumab.
One of these ADCs, sigvotatug vedotin (SV), targets integrin beta-6 (IB6), a protein associated with tumor progression and poor prognosis in several cancers. The Phase 1 trial explores SV in patients with non-small cell lung cancer and head and neck squamous cell carcinoma, showing early signs of promising anti-tumor activity when paired with immune checkpoint blockade.
The second ADC, PDL1V (PF-08046054), is a PD-L1 directed agent under investigation in head and neck cancers. The results from these studies support Pfizer’s broader strategy to develop rational, biology-driven combinations aimed at improving efficacy without compromising safety.
In addition, exploratory analyses from the pivotal EV-302 trial will be shared, examining PADCEV® (enfortumab vedotin) in combination with KEYTRUDA® (pembrolizumab) in patients with previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC). These data are expected to provide deeper insights into biomarkers and subgroups that may benefit most from this dual approach.
Advancing Epigenetic Therapies in Breast and Prostate Cancer
The company will also highlight early-stage findings that could guide future registrational strategies for emerging epigenetic therapies. This includes updates from Phase 1 trials of two novel agents: mevrometostat, an EZH2 inhibitor under evaluation in combination with XTANDI in metastatic castration-resistant prostate cancer (mCRPC), and PF-07248144, a potential first-in-class KAT6 inhibitor being developed for ER+/HER2- metastatic breast cancer.
These agents target key epigenetic regulators that play a role in gene expression and tumor growth, representing a new frontier in precision oncology. The results presented at ASCO will help refine dosing and inform future trial designs as Pfizer prepares to scale up to late-stage clinical development.
Strategic Pipeline Advancement and Future Outlook
Reflecting on the company’s strategy, Megan O’Meara, Head of Early-Stage Development and Interim Head of Late-Stage Development for Pfizer Oncology, emphasized the company’s dual focus on innovation and execution.
“Our data at ASCO this year reflect how we are strategically progressing our deep pipeline of next generation cancer medicines while simultaneously extending the impact of our foundational therapies to reach more people living with cancer,” said O’Meara. “Important early-stage updates highlight our extensive pipeline and depth within our core cancer types, as we advance up to nine new pivotal Phase 3 trials this year.”
With a blend of transformational late-stage data and promising early-phase assets, Pfizer’s presence at ASCO 2025 underscores its ambition to not only remain at the forefront of cancer care but also shape the future landscape with novel modalities, combinations, and biomarker-driven approaches. As the oncology community gathers in Chicago, Pfizer’s expansive data presentations will be closely watched, potentially setting the tone for the next wave of therapeutic innovations in oncology.
